265 related articles for article (PubMed ID: 21632857)
1. Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients.
Morse MA; Chapman R; Powderly J; Blackwell K; Keler T; Green J; Riggs R; He LZ; Ramakrishna V; Vitale L; Zhao B; Butler SA; Hobeika A; Osada T; Davis T; Clay T; Lyerly HK
Clin Cancer Res; 2011 Jul; 17(14):4844-53. PubMed ID: 21632857
[TBL] [Abstract][Full Text] [Related]
2. Toll-like receptor agonists shape the immune responses to a mannose receptor-targeted cancer vaccine.
He LZ; Weidlick J; Sisson C; Marsh HC; Keler T
Cell Mol Immunol; 2015 Nov; 12(6):719-28. PubMed ID: 25345808
[TBL] [Abstract][Full Text] [Related]
3. CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.
Morse MA; Bradley DA; Keler T; Laliberte RJ; Green JA; Davis TA; Inman BA
Expert Rev Vaccines; 2011 Jun; 10(6):733-42. PubMed ID: 21692696
[TBL] [Abstract][Full Text] [Related]
4. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205.
Dhodapkar MV; Sznol M; Zhao B; Wang D; Carvajal RD; Keohan ML; Chuang E; Sanborn RE; Lutzky J; Powderly J; Kluger H; Tejwani S; Green J; Ramakrishna V; Crocker A; Vitale L; Yellin M; Davis T; Keler T
Sci Transl Med; 2014 Apr; 6(232):232ra51. PubMed ID: 24739759
[TBL] [Abstract][Full Text] [Related]
5. Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells.
Ramakrishna V; Vasilakos JP; Tario JD; Berger MA; Wallace PK; Keler T
J Transl Med; 2007 Jan; 5():5. PubMed ID: 17254349
[TBL] [Abstract][Full Text] [Related]
6. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
[TBL] [Abstract][Full Text] [Related]
7. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant.
Kass E; Panicali DL; Mazzara G; Schlom J; Greiner JW
Cancer Res; 2001 Jan; 61(1):206-14. PubMed ID: 11196163
[TBL] [Abstract][Full Text] [Related]
8. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines.
Disis ML; Bernhard H; Shiota FM; Hand SL; Gralow JR; Huseby ES; Gillis S; Cheever MA
Blood; 1996 Jul; 88(1):202-10. PubMed ID: 8704175
[TBL] [Abstract][Full Text] [Related]
9. Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens.
Disis ML; Shiota FM; McNeel DG; Knutson KL
Immunobiology; 2003; 207(3):179-86. PubMed ID: 12777059
[TBL] [Abstract][Full Text] [Related]
10. Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma.
Chakraborty NG; Sporn JR; Tortora AF; Kurtzman SH; Yamase H; Ergin MT; Mukherji B
Cancer Immunol Immunother; 1998 Sep; 47(1):58-64. PubMed ID: 9755879
[TBL] [Abstract][Full Text] [Related]
11. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
[TBL] [Abstract][Full Text] [Related]
12. A novel human cancer vaccine elicits cellular responses to the tumor-associated antigen, human chorionic gonadotropin beta.
He LZ; Ramakrishna V; Connolly JE; Wang XT; Smith PA; Jones CL; Valkova-Valchanova M; Arunakumari A; Treml JF; Goldstein J; Wallace PK; Keler T; Endres MJ
Clin Cancer Res; 2004 Mar; 10(6):1920-7. PubMed ID: 15041707
[TBL] [Abstract][Full Text] [Related]
13. Small cationic DDA:TDB liposomes as protein vaccine adjuvants obviate the need for TLR agonists in inducing cellular and humoral responses.
Milicic A; Kaur R; Reyes-Sandoval A; Tang CK; Honeycutt J; Perrie Y; Hill AV
PLoS One; 2012; 7(3):e34255. PubMed ID: 22470545
[TBL] [Abstract][Full Text] [Related]
14. Targeted Codelivery of an Antigen and Dual Agonists by Hybrid Nanoparticles for Enhanced Cancer Immunotherapy.
Zhang L; Wu S; Qin Y; Fan F; Zhang Z; Huang C; Ji W; Lu L; Wang C; Sun H; Leng X; Kong D; Zhu D
Nano Lett; 2019 Jul; 19(7):4237-4249. PubMed ID: 30868883
[TBL] [Abstract][Full Text] [Related]
15. Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy.
Jeon D; Hill E; Moseman JE; McNeel DG
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38702146
[TBL] [Abstract][Full Text] [Related]
16. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.
Burch PA; Breen JK; Buckner JC; Gastineau DA; Kaur JA; Laus RL; Padley DJ; Peshwa MV; Pitot HC; Richardson RL; Smits BJ; Sopapan P; Strang G; Valone FH; Vuk-Pavlović S
Clin Cancer Res; 2000 Jun; 6(6):2175-82. PubMed ID: 10873066
[TBL] [Abstract][Full Text] [Related]
17. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours.
Conroy H; Marshall NA; Mills KH
Oncogene; 2008 Jan; 27(2):168-80. PubMed ID: 18176598
[TBL] [Abstract][Full Text] [Related]
18. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
[TBL] [Abstract][Full Text] [Related]
19. Dissecting the Immune Stimulation Promoted by CSF-470 Vaccine Plus Adjuvants in Cutaneous Melanoma Patients: Long Term Antitumor Immunity and Short Term Release of Acute Inflammatory Reactants.
Pampena MB; Cartar HC; Cueto GR; Levy EM; Blanco PA; Barrio MM; Mordoh J
Front Immunol; 2018; 9():2531. PubMed ID: 30450100
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity.
Huleatt JW; Jacobs AR; Tang J; Desai P; Kopp EB; Huang Y; Song L; Nakaar V; Powell TJ
Vaccine; 2007 Jan; 25(4):763-75. PubMed ID: 16968658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]